search
Back to results

GWAS in a Small Group of Metabolically Healthy Obese White Adults

Primary Purpose

Obesity

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
GWAS
Sponsored by
University of Nevada, Las Vegas
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Obesity

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • - Adults 40 year old or older
  • Caucasian males or females
  • BMI ≥ 35 kg/m² or history of BMI ≥ 35 kg/m², or BMi less than 25 kg/m2
  • No current or past use of glucose lowering drugs
  • No current or past medical history of diabetes mellitus
  • No current or past medical history of established coronary artery disease (angina, myocardial infraction, abnormal cardiac stress test)
  • No current or past medical history of or treatment for thyroid disorders
  • No current or past use of lipid lowering drugs or diagnosis of a lipid disorder
  • No current or past medical history of or treatment for hypertension
  • Subject's willingness to provide the study investigators with a copy of their medical records or give permission to the study investigators to access the following specific medical information:

    • Fasting plasma glucose (less than 100 mg/dL/5.6 mmol/L)
    • HDL-C cholesterol (more than 40 mg/dL /1.03 mmol/L)
    • Total cholesterol (less than 239 mg/dL/ 6.18mmol/L)
    • LDL cholesterol (less than 159 mg/dL/4.11 mmol/L)

Exclusion Criteria:

  • - Known monogenic forms of obesity
  • Polycystic ovary disease (in women)
  • Malabsorptive or maldigestive syndromes (Celiac disease, Crohn's Disease, inflammatory bowel disease, etc.)
  • Anorexia nervosa or bulimia

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    obese subjects

    lean subjects

    Arm Description

    DNA analysis

    DNA analysis

    Outcomes

    Primary Outcome Measures

    number of SNPs associated with high BMI
    Using GWAS to identify candidate genes associate with obesity (high BMI) in a carefully phenotyped white adults with obesity (as defined by BMI), metabolically healthy, matched with lean, white adults metabolically healthy.

    Secondary Outcome Measures

    Full Information

    First Posted
    March 26, 2014
    Last Updated
    April 2, 2014
    Sponsor
    University of Nevada, Las Vegas
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02105909
    Brief Title
    GWAS in a Small Group of Metabolically Healthy Obese White Adults
    Official Title
    Genome Wide Association Studies (GWAS) to Identify Candidate Obesity Susceptibility Genes in a Carefully Phenotyped, Metabolically Healthy Population of Obese White Adults
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    May 2009 (undefined)
    Primary Completion Date
    November 2013 (Actual)
    Study Completion Date
    November 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Nevada, Las Vegas

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a GWAS pilot study that aims to identified possible candidate genes associate to obesity by exploring single nucleotide polymorphism (SNP) in a small group of obese , metabolically healthy white adults, matched with lean, white adults , metabolically healthy. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with obesity (as defined by BMI).
    Detailed Description
    Between 60%-70% of the risk of obesity appears to be heritable. Unfortunately, the exact genes involved have been difficult to identify. New technologies now exist to help researchers discover obesity susceptibility genes. One of these technologies is the Affymetrix Genome-Wide Human SNP (single nucleotide polymorphism) Array 6.0 chips. SNPs are individual base pair differences in genes of different individuals, and they are the main source of human genetic diversity. The "chips" are thumbnail-size silicon surfaces that contain copies of hundreds of thousands of SNPs of the human genome (in this case around 900,000). SNP chips allow researchers to screen thousands of genes in a single experiment and compare genes of subjects with a particular disease or condition with unaffected control subjects. The investigators study utilizes SNP chips to compare the genetic profiles of obese subjects (N = 20, body mass index > 35 kg/m2) without common obesity-related co-morbidities such as diabetes mellitus or hypertension with well matched, lean controls (N = 20, body mass index 18-25 kg/m2). This is a pilot study intended to explore the following: 1) possible associations between obesity and previously unidentified obesity susceptibility genes; 2) associations between known obesity genes and obesity risk in subjects without obesity-related metabolic co-morbidities; and 3) how well our genetic data conform to other studies in similar populations as a way of assessing if the investigators have identified a representative cohort of obese subjects.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Obesity

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    81 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    obese subjects
    Arm Type
    Experimental
    Arm Description
    DNA analysis
    Arm Title
    lean subjects
    Arm Type
    Placebo Comparator
    Arm Description
    DNA analysis
    Intervention Type
    Other
    Intervention Name(s)
    GWAS
    Primary Outcome Measure Information:
    Title
    number of SNPs associated with high BMI
    Description
    Using GWAS to identify candidate genes associate with obesity (high BMI) in a carefully phenotyped white adults with obesity (as defined by BMI), metabolically healthy, matched with lean, white adults metabolically healthy.
    Time Frame
    baseline

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    40 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: - Adults 40 year old or older Caucasian males or females BMI ≥ 35 kg/m² or history of BMI ≥ 35 kg/m², or BMi less than 25 kg/m2 No current or past use of glucose lowering drugs No current or past medical history of diabetes mellitus No current or past medical history of established coronary artery disease (angina, myocardial infraction, abnormal cardiac stress test) No current or past medical history of or treatment for thyroid disorders No current or past use of lipid lowering drugs or diagnosis of a lipid disorder No current or past medical history of or treatment for hypertension Subject's willingness to provide the study investigators with a copy of their medical records or give permission to the study investigators to access the following specific medical information: Fasting plasma glucose (less than 100 mg/dL/5.6 mmol/L) HDL-C cholesterol (more than 40 mg/dL /1.03 mmol/L) Total cholesterol (less than 239 mg/dL/ 6.18mmol/L) LDL cholesterol (less than 159 mg/dL/4.11 mmol/L) Exclusion Criteria: - Known monogenic forms of obesity Polycystic ovary disease (in women) Malabsorptive or maldigestive syndromes (Celiac disease, Crohn's Disease, inflammatory bowel disease, etc.) Anorexia nervosa or bulimia

    12. IPD Sharing Statement

    Learn more about this trial

    GWAS in a Small Group of Metabolically Healthy Obese White Adults

    We'll reach out to this number within 24 hrs